Navigation Links
Hard to Treat Diseases (HTDS) clinical trial protocol for MMR Vaccine expected Q2 2009
Date:3/27/2009

SHENZEN, China, March 27 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com Today after the market closed the company announced the clinical trial protocol for their MMR Vaccine is under preparation, and is expected to be approved by the end of the second quarter 2009.

The MMR Vaccine is a mixture of three live attenuated viruses administered via injection for immunization against measles, mumps, and rubella (also called German measles). It is generally administered to children around the age of one year, with a second dose before starting school (i.e. age 4/5).

Prior to the widespread use of a vaccine against measles, its incidence was so high that infection was felt to be inevitable. Today, it is widely used around the world, and since introduction of its earliest versions in the 1970s, more than 500 million doses have been administered in over 60 countries. The incidence rate has fallen to a low of less than 1% of people under the age of 30 in countries with routine childhood vaccination.

The company will provide further details as they become available.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, readers should contact the company directly at corporate@htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Microsurgery May Cut Swelling After Breast Cancer Treatment
2. Treatment Target for Herpes Pinpointed
3. Plastic Surgeon Allan Parungao, MD, FACS, Announces Clinical Trial of Juvderm Technique to Treat Root Cause of Midface Sagging, without Surgery
4. Individualized stroke treatment available for patients, though underutilized
5. New Guidelines for Treating Heart Failure
6. New OTC Allergy Treatment Available to Food Allergy Sufferers
7. Combating weight gain caused by antipsychotic treatments
8. Autism Study Finds Significant Benefit with Hyperbaric Treatment
9. NeuroVasx Receives CE Mark for cPAX Aneurysm Treatment System
10. Surveyed Experts Indicate that Biogen Idecs Adentri Has Advantages Over Nitroglycerin in the Treatment of Acute Heart Failure
11. Autism Website Relaunches to Offer Resources, Treatments and Hope for Families
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... August 21, 2017 , ... Five chefs from local senior ... Alzheimer’s Family Center. , Guests will be able to vote for their favorite ... Lamb Shank with Fennel Dill Salad, Feta Cheese Sauce & Garlic Pita Crisp, Greek ...
(Date:8/21/2017)... ... August 21, 2017 , ... PIXACORE , an independent full-service agency with ... 100 agencies of the year by MM&M. , This is the first time PIXACORE ... milestone for the agency. PIXACORE’s newfound recognition reflects its steady trajectory of growth ...
(Date:8/21/2017)... Atlanta, GA (PRWEB) , ... August 21, 2017 , ... ... International Design Excellence Awards (IDSA IDEA®) 2017 Ceremony and Gala on Aug. 19, ... Silver in one of the world’s most prestigious and rigorous design competitions. See all ...
(Date:8/20/2017)... Centennial, CO (PRWEB) , ... August 20, 2017 , ... ... in the same household? If so, you may be interested in participating in ... The purpose of this research is to understand more about the relational aspects of ...
(Date:8/19/2017)... ... August 18, 2017 , ... ... Act of 2017, legislation that provides for greater public access to over-the-counter (OTC) ... loss to access OTC hearing aids without being seen by a certified and ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Aug. 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the ... quarter ended June 30, 2017.  All comparisons, unless otherwise noted, ... Second Quarter 2017 Highlights include: ... $1,089 million, an increase of 3.5% Total ... Gross margin of 7.5% versus 7.6% ...
(Date:8/4/2017)... Aug. 3, 2017  Agragen, LLC, a ... in the biopharmaceutical, nutraceutical, and aquacultural feed sectors, ... its lead drug candidates, AGR131.  This drug is ... from the blood of patients suffering from inflammatory ... bowel disease. ...
(Date:8/2/2017)... BENTON, Ky. , Aug. 2, 2017   Marshall County Hospital in ... (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). The new addition, ... uses UVC light energy to kill deadly pathogens such as C. diff , MRSA, ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
Breaking Medicine Technology: